Testing abemaciclib with chemo before breast cancer surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if adding abemaciclib (a targeted pill) to standard chemotherapy before surgery can shrink HR+/HER2- breast cancer and allow less extensive surgery. It also aims to see if a genetic test (Oncotype DX) can help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman at least 18 years old
- Your breast cancer is hormone receptor positive (HR+) and HER2 negative
- Your cancer is stage II or III and hasn't spread to distant organs
- You are healthy enough for daily activities (ECOG 0 or 1)
- You are not pregnant and agree to use effective non-hormonal birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
This trial tests whether the drug abemaciclib can help women with hormone receptor-positive, HER2-negative breast cancer who still have signs of cancer DNA in their blood after standard treatment. It aims to prevent a future return of the cancer.
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
This trial tests a combination of two drugs (imlunestrant and abemaciclib) given before surgery for a type of breast cancer that is hormone-receptor positive and HER2 negative. The goal is to see if this treatment shrinks the tumor enough to improve surgery outcomes.
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.